Anti-Coagulants - Sudan

Sudan

The revenue in Sudan's Anti-Coagulants market is estimated to reach US$1.80m in 2024.
It is expected to experience an annual growth rate of 5.75% between 2024 and 2029, leading to a market volume of US$2.38m by 2029.
When comparing globally, United States is projected to generate the highest revenue of US$16,740.00m in 2024.
In Sudan, the demand for anti-coagulants is surging due to an aging population and an increase in cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

Anti-Coagulants, also known as blood thinners, are medications that help prevent blood clots. In Sudan, the Anti-Coagulants market has been developing steadily over the years due to various factors.

Customer preferences: Sudanese customers prefer Anti-Coagulants that are affordable and easily accessible. They tend to opt for generic brands over branded ones due to the cost difference. However, they also prioritize quality and efficacy when it comes to choosing the medication.

Trends in the market: One of the major trends in the Sudanese Anti-Coagulants market is the increasing prevalence of cardiovascular diseases. This has led to a rise in demand for Anti-Coagulants as they are an essential component of the treatment plan for such diseases. Another trend is the growing awareness about the importance of preventive healthcare, which has led to an increase in the number of people taking Anti-Coagulants as a precautionary measure.

Local special circumstances: Sudan has a high prevalence of malaria, which can increase the risk of blood clots. This has led to an increased demand for Anti-Coagulants as a preventive measure. Additionally, the country has a large population of elderly individuals who are more prone to developing cardiovascular diseases, further increasing the demand for Anti-Coagulants.

Underlying macroeconomic factors: Sudan has been facing economic challenges in recent years, which has led to a decline in the purchasing power of its citizens. This has resulted in a greater demand for affordable Anti-Coagulants. Furthermore, the country has a weak healthcare infrastructure, which has made it difficult for patients to access quality healthcare services. As a result, there has been a greater reliance on self-medication and over-the-counter drugs, including Anti-Coagulants.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.